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ABSTRACT 
Objective:  Type III endoleaks (T-III) following endovascular repair of aortic aneurysms 
(EVAR) remain a major concern.  Our center experienced a recent concentration of T-III 
endoleaks requiring elective and emergency treatment and prompted our review of all EVAR 
implants over a 40 month period from April 2011 until August 2014.  This report represents a 
single center experience with T-III endoleak management with analysis of factors leading to the 
T-III related failure of EVAR. 
Methods:  A retrospective review of all the operative reports, medical records and computed 
tomography scans were reviewed from practice surveillance.  Using SVS aneurysm reporting 
standards, we analyzed the morphology of the aneurysms before and after EVAR implant using 
computed tomography (CT).  Index procedure and frequency of reinterventions required to 
maintain aneurysm freedom from rupture were compared across all devices using SAS version 
9.4 (SAS Institute, Inc. Cary, NC.).  .   Major adverse events requiring secondary interventions 
for aneurysm treatment beyond primary implant were analyzed for methods of failure.  
Aneurysm morphology of patients requiring EVAR was compared across all endograft devices 
used for repair.  For purposes of major adverse event analysis, patients receiving Endologix 
(ELX) endograft were combined into Group 1 and Gore, Cook and Medtronic endograft patients 
were placed into Group 2. 
Results:  Overall technical success and discharge survival was achieved in 97.3% and 98% of 
patients regardless of device usage.  There was no significant device related difference identified 
between patient survival or freedom from intervention.  Major adverse events involving 
aneurysm treatment were over 7 fold more frequent with ELX (Group1) vs non-ELX (Group 2) 
endografts (p<0.01). Group 1 patients with aneurysm diameters larger than 65 mm were 
associated with a highly significant value for development of a T-III endoleak (OR=11.16, 95% 
CI (2.17, 57.27); p=0.0038). 
Conclusions:  While EVAR technical success and survival was similar across all devices, ELX 
devices exhibited an unusually high incidence of Type III endoleaks when implanted in AAA 
with a diameter of more than 65 mm.  Frequent reinterventions were required for Endologix 
devices for prevention of aneurysm rupture due to T-III endoleaks. 
INTRODUCTION:  Endovascular management of abdominal aortic aneurysms (EVAR) has 
become an accepted form of repair since the initial report by Parodi1.   In 2009, the Division of 
Vascular Surgery at Indiana University initiated a Level 1 Acute Aortic program designed to 
centralize rapid response, transport and treatment of aortic emergencies within the state of 
Indiana and surrounding area.  All FDA approved and commercially available devices were used 
in our practice with preponderance of the use of Endologix endografts.  In 2013, a concentration 
of reinterventions for Type III (T-III) endoleak treatment raised concern over device selection 
and prompted a review of all patients having EVAR repair with FDA approved endografts. 
Methods:  Using SVS/AAVS reporting standards, we obtained variables from the index 
procedure which included timing of repair, AAA neck and sac morphology, age, medical co-
morbidities, correlation of AAA repair with manufacturer’s instructions for use, technical 
success and  presence of endoleak at the completion of the procedure 2. 
Indications for EVAR repair included all standard indications and specifically symptomatic or 
ruptured AAA; elective AAA size exceeding 5.5 cm in a male and > 5 cm in a female; saccular 
aneurysms regardless of size; enlarging aneurysms with size increase of > 0.5 cm in 6 months; 
atheroembolism attributed to aneurysmal disease and pre-transplant patients having AAA 
exceeding 3 cm (as per protocol). Technical success was defined as satisfactory endograft 
placement with exclusion of the aneurysm sac, maintaining patent renal vessels and absence of 
Type I or Type III endoleaks at the completion of the procedure.  Mortalities were reviewed from 
medical records and from last known contact to determine if they were device related.  For 
analysis, patients receiving an endograft from Endologix (Powerlink or AFX - Irvine, CA) were 
identified as Group 1. Patients receiving endografts from Gore (Excluder-Flagstaff, AZ), Cook 
(Zenith- Bloomington, IN) or Medtronic (Endurant- Minneapolis, MN) manufacturers were 
identified as Group 2.    AAA freedom from re-intervention was assessed at any point of 
aneurysm reintervention as a binary numeral.    Patient survival was documented at completion 
of the index procedure, at any re-intervention and from last available patient contact.  
Freedom from intervention was defined as the absence of any singular event required for 
aneurysm treatment and independent of the number of reinterventions encountered.  Any 
indication for aneurysm treatment, timing of repair, repair method and procedural success was 
noted.   Major Adverse Events (MAE) defined the cumulative sum of events involving any 
device related mortality + post-implant aneurysm rupture + any operative conversion and all 
aneurysm reinterventions required to maintain freedom from aneurysm rupture.   Major adverse 
events were then tabulated for each group and independently for each patient. 
The remainder of the study focused on the cohort of patients receiving an Endologix endograft 
(Group 1).  IFU information was abstracted from Endologix manufacturer’s “Instructions For 
Use” in the Powerlink XL pivotal US FDA trial in 2008 and later amended for AFX product 
update.  An IFU Outlier was defined as any one of the following: aortic diameter < 18 or > 32 
mm, aortic neck length of < 15mm, or aortic (Ao) neck angle > 60 degrees.  AAA size, aneurysm 
neck angle change, measurements of centerline and device overlap and documentation of 
endoleak by computed tomography (CT) was monitored over time at all available follow up 
visits.    Overlap was defined as the length of wireframe duplication observed between an aortic 
bifurcated unibody and the proximal aortic extension.  Centerline change was defined as the 
length of the central flow lumen from lowest renal artery to aortic bifurcation occurring over 
time from the index procedure.  Variables recorded from routine follow up included freedom 
from aneurysm re-intervention, AAA size, endoleak presence and centerline and overlap 
measurements. 
Statistical Analysis:  All information was stored in Redcap: a research electronic database 
capture provided by the Indiana Clinical and Translational Sciences Institute as a secure web 
application for managing surveys and databases3.  This study met requirements for Indiana 
University IRB expedited review with patient consent waived.  Statistical analysis was 
performed using SAS version 9.4 (SAS Institute, Inc. Cary, NC.).  Odds Ratios for Type III 
endoleak occurrence, Chi square and Fischer’s Exact test to account for low expected cell counts 
were used in univariate analysis of patient reinterventions.  Pre-operative and procedural 
variables were submitted for ANOVA and multivariable-logistic regression analysis.  Kaplan-
Meier curve was used to plot patient survival.    All analytic assumptions were verified to ensure 
results validity.   A p value less than 0.05 was considered statistically significant. 
RESULTS:  There were a total of 151 patients, 83 having an ELX endograft (Group 1) while 
68 received a Cook, Gore or Medtronic device (Group 2).  Table I  One hundred thirty two 
patients were alive at the completion of the study; Group 1= 71, Group 2 = 61 (p=0.3025). 
Technical success was achieved in 97.3% (147/151) for EVAR placement, with no difference 
between either group (p = 0.2525).  Similarly, over 98% of patients were discharged alive 
following their EVAR procedure.  There were four deaths that occurred during the index 
hospital stay:  three from aneurysm rupture and one from operative conversion for an 
unresolved Type Ia endoleak.  Over the course of the study, eighteen deaths were recorded 
with twelve in Group 1 and six in Group 2 (p=0.2451 overall). Table II  Four mortalities 
were deemed device related (DR) which included one operative conversion during the index 
hospital stay and three deaths following emergent reintervention treatment, all in Group1 (p 
=0.1274). 
No statistical significant difference was noted when the following variables were compared 
per group: sex, age, pre-op co-morbidity risk factors, and timing of repair, AAA size, or 
choice of endograft.  
Survival analyses indicate that there were no significant differences in the time until death 
or re-intervention from surgery (p>0.05).  Figure 1 shows the Kaplan-Meier survival curve 
on time since surgery for mortality, with other survival analyses having similar KM curves. 
Group 1 centerline change greater than 10 mm from baseline proved non-significant also: 
OR = 3.64 (CI 0.81-16.33), p = 0.0910. 
 
Major Adverse Event occurrences for Group 1 totaled thirty eight versus five in Group 1. Table 
II   Categories of MAE in Group 1 (N= 38) include: DR mortality N = 4, AAA rupture N =8, OR 
conversion N = 2 and AAA reintervention N = 24.  Twelve patients with T-III endoleaks 
accounted for 76% (29/38) of MAE’s: (DR mortality = 2, post implant AAA rupture = 7, AAA 
reintervention = 20).  
Statistical significance between groups was discovered in the following variables: aortic 
neck diameter (p= 0.0179), aortic neck length (p=0.0016), aortic neck angle (p=0.0101), 
AAA angle (p=0.0045), Major Adverse Event rate (<0.0001), post implant rupture rate (p = 
0.0084) and total number of aneurysm re-interventions (p = 0.0008). 
All T-III events occurred in Group 1 (ELX). Table III   Regression analysis identified 
AAA diameter > 65 mm as a predictor for Type III endoleak (OR=11.16, 95% CI (2.17, 
57.27); p=0.0038).  While differences were seen between groups for aortic neck 
measurements as noted above, only AAA diameter achieved significance for T-III 
endoleaks in Group 1 only. 
DISCUSSION: Since EVAR’s inception, stent-graft design modifications have made 
EVAR a safe and durable procedure for AAA repair. Safety profiles of the eight FDA 
approved endovascular stent grafts are well established 4, 5, 6, and 14.   Surveillance 
monitoring for EVARs remain a critical part of AAA care to maintain freedom from 
rupture.  One recognized method of EVAR failure is development of a Type III endoleak 
which can return aortic sac pressures to systemic levels. Endovascular repair for component 
separation (T-IIIa) of a modular endograft can often be accomplished by bridging the gap 
with an additional iliac limb extension, while a fabric tear (T-IIIb) may require relining an 
involved limb or the entire device to avoid need for open conversion. ELX device T-IIIa 
endoleaks are unique in that separation involves aortic components requiring bridging of 
additional aortic extension(s) and their inherent larger sheaths to complete a repair. ELX 
device T-IIIb endoleaks are more commonly attributed to the bifurcated unibody device 
which occurs near the saddle of the endograft.  Relining the entire endograft is 
recommended given the difficulty in pinpointing the exact location and extent of the defect.  
In contrast to all other endograft designs, the ELX endoskeleton can prove challenging with 
reinterventions to avoid wireframe entrapment. Currently no evidence exists as to whether 
repair of T-III endoleaks should be accomplished with like (similar) devices or with 
alternative endograft products.  Both techniques were utilized in this series and similar 
outcomes were noted. 
The Endologix endoskeletal design for both Powerlink and AFX stent grafts provide 
maximum flexibility in conforming to AAA morphology.  The bifurcated unibody design, 
ease of length adjustment for overlap at the time of implant and rapid deployment system 
allow for elective, urgent and emergent AAA repair with one sheath delivery.  Several 
reports have documented its safety record in longitudinal AAA care 7, 8, and 9.  Flexibility in 
the endoskeletal design, however, may be detrimental to lateral stability especially when a 
large diameter aneurysm is treated as distraction forces impact component overlap to a 
greater degree than caudal or cephalad migration of aortic and iliac seal zones.  We 
hypothesize that fabric billowing of the proximal aortic extension may provide a reverse 
windsock effect that increases distraction forces between the bifurcated unibody stent graft 
and the proximal aortic extension by cephalad displacement that can ultimately cause an 
uncoupling of the two components.  This appears more pronounced with aneurysms of 
larger size (65mm) and may be accentuated when diameters of the bifurcated unibody stent 
graft and the aortic extension differ significantly.  The mean AAA size for patients with T-
IIIa endoleak in this study was 80.5 mm.  All six patients experiencing T-IIIa in this report 
had a 25 or 28 mm diameter bifurcated unibody stent graft coupled with a 34 mm proximal 
aortic extension. 
Similar to prior reports, we found no difference between patient survival and freedom from any 
intervention between the two groups 4, 10, 11, 12.   Significant differences were noted between 
Groups for Aortic Neck diameter (p =0.0179), Aortic neck length (p= 0.0016), Aortic neck angle 
(p = 0.0101) and Aneurysm angle (p =0.0045) measurements.  All of these values are well within 
the IFU recommendations of all devices used, so clinical relevance of these values is uncertain.   
While there was no difference between Groups in freedom from reintervention , we found a large 
difference in MAE’s not previously reported as several of our patients experienced more than 
one MAE at different episodes of treatment (range  0-5) (p< 0.0001).  Post implant rupture rate 
and AAA reintervention proved to be also highly significant between Groups. 
While not statistically significant, all T-IIIa patients in this series did develop increasing 
centerline measurements and decreasing component overlap prior to IIIa endoleak discovery. 
This is likely due to the extended length of follow up imaging obtained during routine 
surveillance for stable aneurysms.  Our 7.2% (6/83) incidence of T-IIIa is more than double that 
reported by Endologix Core Lab analysis of 3.1% (4/127).   Based on post-market report 
findings, Endologix now recommends: 1) maximizing component overlap greater than 
previously recommended 40 mm, 2) avoidance of excessively oversized extension relative to the 
bifurcated unibody stent graft and 3) use of a third overlapping component to increase columnar 
strength in AAA larger than 70 mm. 
The large number of T-IIIb endoleaks (N=8) found in Group 1 ELX patients is unique and at 
odds with reported rates of 0.22% worldwide (Endologix Clinical Update June 2, 2015.).    No 
relationship could be found between device implantation, surgeon, completion balloon 
angioplasty, or AAA morphology except for size greater than 65 mm.  Time to T-IIIb 
presentation varied between 6 and 51 months (Table III).   Most of the IIIb endoleaks appeared 
to involve the bifurcated unibody stent graft although post hoc analysis proved difficult to assign 
an exact location as can be seen in Figure 2.  All surveillance CT scans evaluated before IIIb 
presentation by the treating vascular surgeon were interpreted as unremarkable and demonstrated 
stable or shrinking aneurysm sacs over time. 
In an October 2014 product update, Endologix announced a change in their ePTFE fabric from 
Strata® to Duraply®, citing “a high density multilayered design to bolster strength 
characteristics”.  All patients in this study received devices of Powerlink or AFX system having 
Strata® fabric predating Duraply®.  It remains unclear if the change in fabric design to Duraply 
will provide greater security in preventing T-IIIb endoleaks. 
We found the cobalt chromium wireframe visualization of the ELX stent grafts assessment 
challenging in comparison CT studies for overlap determination.  Plain film radiographs are a 
better choice than CT scans to monitor this change.   Observations from our study will strengthen 
the need for further design modification requirements required for the device in order to monitor 
the overlap between components.  Similarly, we believe a conventional duplex scan exam to 
monitor sac morphology during the post implant period may not help predict impending T-IIIA 
endoleak.  We propose that combinations of CTA with plain radiograph films are required during 
the surveillance period. 
This study has several limitations.  It is retrospective and from a single center experience. A 
small sample size may have prevented observed trends to demonstrate statistical significance.  
EVAR monitoring was at the discretion of the treating vascular surgeon. Selection bias may have 
occurred with endograft selection although no difference in patient survival or freedom from 
reintervention could be identified between elective vs emergent procedures.  In contrast to open 
repair, EVAR monitoring requires continued surveillance for endoleak detection and to verify 
device integrity to maintain freedom from AAA rupture.  The practitioner’s role in surveillance 
remains critical.  Practice variation can produce disparate EVAR outcomes among providers 
with like stent graft devices.  Most notable in this review were differences in CT scan technique 
from multiple imaging centers and a lack of uniform time in follow up surveillance imaging.  
This decreased the strength of centerline and overlap end points as several imaging studies 
lacked the capability for reformatting acquired images (slice thickness equal or exceeding 4 
mm). 
Several observations can be made based on our scrutiny of imaging studies from initial EVAR 
repair to all available surveillance scans.  First, our ELX cohort represented approximately 55% 
(83/151) of all EVAR procedures performed at our institution between April 2011 and August 
2014.   Device selection was at the vascular surgeons’ discretion.  No selection bias was 
discovered between ELX and alternative stent graft use with regards to AAA morphology, 
calcification or neck anatomy.  Our freedom from reintervention rate for (non-ELX patients) of 
7.3% is not significantly different from the 14.4% incidence for the ELX group. Nonetheless,   
repeated interventions (N =20) were necessary in the ELX group of patients exhibiting T-III 
complications who required multiple procedures to prevent aneurysm rupture while no additional 
procedures were necessary in the non-ELX group.  Second, appropriate “like” sized ELX device 
selection is critical in large aneurysms as T-IIIa risk appears increased when there are marked 
differences in diameter between the unibody and aortic extension components.  Maximizing 
device overlap beyond 40 mm and adding a third device as a multilayer component for larger 
size AAA appears logical to potentially minimize both lateral and cephalad distraction forces 
that predispose to T-IIIa development.  Obtaining bimodal imaging at the time of EVAR repair 
with AP and oblique views may also help to identify those patients with extreme endograft 
angulation.  Currently, the largest bifurcated unibody device diameter is 28 mm.  All patients 
with T-IIIA separation in this series received a 34 mm diameter aortic extension necessary for 
proximal aortic neck diameters. This combination continues to prove challenging in patients with 
large aneurysms. Third, protocol surveillance with CT imaging appears preferable over 
ultrasound to monitor changes in centerline length and device overlap observed over time, 
potentially identifying those patients at risk for T-IIIa development.  We currently have treated 
two patients for centerline changes electively to avoid potential T-IIIa development.   Fourth, our 
large concentration of IIIb endoleaks in this cohort remains unexplained and unpredictable as to 
onset and incidence.  It is our belief that Endologix patients treated before October 2014 remain 
at risk for fabric deterioration and specifically those with AAA greater than 65mm should have 
regularly scheduled CT imaging to continue verifying endograft stability.  As Hertzer implies, 
“Results mean everything”, so it is incumbent on us to remain good stewards to AAA care with 
EVAR device use13. 
Conclusion: Patients with AAA diameter > 65 mm may have an increased risk for T-III 
complications with the ELX graft.  CT imaging is recommended over ultrasound to monitor 
device overlap and centerline changes that may occur over time to avoid Type IIIa endoleak.  
While freedom from intervention remains similar between endograft groups, major adverse 
events are frequent and markedly increased in ELX patients that require further aneurysm 
treatment. Type IIIb endoleak development was found unrelated to AAA morphology yet 
appears linked to AAA size and to fabric design.  Our results call for continued surveillance in 
patients treated with ELX devices especially in those treated prior to October 2014 with CT 
imaging recommended as the primary imaging modality. 
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Table I 
Patient Demographics and Pre-op Variables 
Variable                Group 1 (ELX) n=83  Group 2 (non-ELX) n=68   P-value 
Age    71.0 (9.60)   72.14 (8.64)  0.4485 
Male    71 (56.4%)   55 (43.7%)  0.4434 
Cardiac status 
 0-2   56 (67.4)   54 (79.4)  0.3379 
 3-4   27 (32.5)   13 (20.5) 
Pulmonary 
 0-2   72 (86.7)   60 (88.2)  0.1514 
 3-4   7 (8.4)    8 (11.8) 
Renal 
 0-2   77 (92.7)   65 (95.6)  0.8259 
 3-4    5 (6.0)     3 (4.4) 
Hypertension 
 0-2   44 (53.0)   35 (51.5)  0.7754 
 3-4   39 (46.9)   33 (48.5) 
Ao Neck diameter  25.58 (4.19)   24.01 (3.50)  0.0179 
Ao Neck Length   25.22 (14.32)   33.69 (16.82)  0.0016 
Ao Neck angle   19.11 (16.20)   26.30 (15.48)  0.0101 
AAA angle   38.38 (20.27)   47.74 (16.48)  0.0045 
IFU Outlier   10 (13.3)   3 (4.7)   0.0810 
AAA size   62.56 (15.07)   60.79 (12.30)  0.4254 
Timing 
 Elective   55 (66.3)   43 (63.2)  0.6297 
 Urgent   8 (9.6)    10 (14.7) 
 Emergent  20 (24.1)   15 (22.1) 
Technical Success  79 (95.2)   67 (98.5)  0.2525 
Procedure Survival  79 (95.2)   68 (100)   0.1111 
Overall Survival                71 (85.5)               61 (91.0)                0.3025 
Freedom from Int (No)               12 (14.5)               5 (7.4)1                0.2025 
Major Adverse Events total 38                 5                <0.0001 
    Patient MAE mean/range 0 (0-5)                0 (0-1)         
Type III endoleak 
 IIIa    6                                          0              <0.0001 
 IIIb    8               0 
 
1One patient declined treatment in Group 2. 
Freedom from Int (No) = Patient requiring post implant AAA treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table II 
Major Adverse Events 
Event Type    Group 1(n)   Group 2(n) p-value 
Device Related Mortality                    4       0  0.1274 
Post Implant Rupture       8 (T-III = 7)      0  0.0084 (.0166) 
OR Conversion                     2       0  0.5016 
AAA Reintervention       24 (T-III =20)      5  0.0008 (.0076) 
 
Total         38       5 
Legend: AAA Reinterventions include: Limb extension for aneurysmal disease; Limb occlusion; Endoleak 
treatment; Centerline increase with concern for IIIA endoleak; Renal artery treatment. (T-III patients accounted for 
7/8 post implant ruptures and 20/24 AAA reinterventions).  Second p-value is for T-III only frequencies.                                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table III 
Reinterventions in Patients with Type III Endoleak 
           Pt Number AAA (mm) Ao Neck 
Angle 
Case Type    Event Interval 
      (Months) 
Event Event survival 
70 80.2 55 Urgent          18                  IIIa       Y 
 
72 79 39 Emergent 
Elective 
         16 
         20  
IIIb 
Ib 
      Y 
      Y 
 
98 54 6 Emergent          12 IIIb       Y 
 
101 53 67 Elective 
Emergent 
         46 
         51 
IIIa 
IIIb 
      Y 
      Y 
      
102 80 NA 
 
Emergent 
Emergent 
Emergent     
         32 
         35 
         35 
IIIa 
IIIb 
ALI 
 
      Y 
      Y 
      N 
    
105 111 24 Elective         
Urgent 
Emergent 
           3                                   
         16 
         25  
Ib                 
Ia 
IIIa 
      Y 
      Y 
      Y 
  Emergent 
 
         42 IIIb       N 
 
107 88 45 Urgent          11 IIIb       Y 
      
114 91 51 Elective 
Elective 
           3 
          20 
Iliac 
CL 
      Y 
      Y 
 
142 
 
150 
41 
 
78 
19 
 
10 
Elective 
 
Urgent 
           6 
           
          26  
IIIb 
 
IIIa 
      Y 
 
      Y 
 
151 
 
152 
 
81 
 
52 
30 
 
 8 
Elective 
 
Elective 
          36 
           
          36 
IIIa 
 
IIIb               
      Y 
 
      Y 
 
 
 
Legend: Endoleak = Ia, Ib, IIIa, IIIb; ALI = Acute Limb, Ischemia; Iliac = Limb extension;  
CL = Centerline Increase 
AAA diameter > 65mm association with T-III endoleak: (OR=11.16, 95% CI (2.17, 57.27) p = 0.0038). 
  
 
Figure 2: 111 mm Ruptured Aneurysm with consecutive emergent T-IIIa and T-IIIb events.  Open conversion 
required after 4 Major Adverse Events 
 
 
 
 
 
Figure 1
 
Figure 3: Kaplan-Meier survival curve for mortality over time since surgery, showing no difference between strata 
(ELX vs. others); p=0.1354. 
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